Resveratrol as an Anti-inflammatory Agent in Coronary Artery Disease:A Systematic Review,Meta-Analysis and Meta-Regression  

作　　者：Vito A.Damay Ignatius Ivan 

机构地区：[1]Department of Cardiovascular Medicine,Universitas Pelita Harapan,Tangerang,Banten,15811,Indonesia [2]Jakarta Varices Clinic,Jakarta,12210,Indonesia

出　　处：《Chinese Journal of Integrative Medicine》2024年第10期927-937,共11页中国结合医学杂志（英文版）

摘　　要：Background:Resveratrol is a non-flavonoid polyphenol that shows promise in reducing proinflammatory factors and maintaining endothelial function,which hints at its potential role in slowing atherosclerosis and preventing acute coronary events.Objective:To study the cardioprotective effects of resveratrol on inflammatory mediators and endothelial function in patients with coronary artery disease(CAD).Methods:A thorough search was conducted in databases(Cochrane Library,Pro Quest,Pub Med,LILACS,Science Direct,Springer,Taylor&Francis,CNKI,Wanfang,and Weipu)until September 24,2023.The vasopro-inflammatory mediators,endothelial function and outcomes related to cardiovascular events were observed.Titles and abstracts were assessed,and bias was evaluated with Cochrane Ro B 2.0.Heterogeneity of results was explored by metaregression,certainty of evidence was assessed by the GRADE system,and conclusive evidence was enhanced by trial sequence analysis.Results:Ten randomized controlled trials and 3 animal studies investigated resveratrol's impact on inflammatory mediators and endothelial function.In primary prevention studies,meta-analysis showed a significant reduction(95%CI:–0.73 to–0.20;P=0.0005)in tumor necrosis factor-α(TNF-α)expression with resveratrol,demonstrating a dose-dependent relationship.No significant difference was observed in interleukin-6(IL-6)expression with P=0.58 for primary prevention and P=0.57 for secondary prevention.Vascular endothelial nitric oxide synthase(e NOS)expression was significantly increased after resveratrol pre-treatment following CAD events.Secondary prevention studies yielded no significant results;however,meta-regression identified associations between age,hypertension,and lower doses with the extent of TNF-αalterations.High certainty of evidence supported TNF-αreduction,while evidence for IL-6 reduction and e NOS elevation was deemed low.Conclusions:Resveratrol reduces TNF-αin individuals at risk for CAD,specifically 15 mg per day.However,its usefulness in patients with co

关 键 词：ANTI-INFLAMMATION coronary artery disease nitric oxide RESVERATROL systematic review 

分 类 号：R256.22[医药卫生—中医内科学]